Cancer-Drug Bills at Portugal's Hospitals Have Tripled in a Decade, Reaching €320 Million by April

The cost of treating cancer in Portugal's hospitals has climbed relentlessly, with spending on oncology medicines more than tripling over the past decade. In the first four months of 2026 alone, public hospitals spent €915.1 million on medicines of all kinds, of which €320.1 million — roughly 35% — went on cancer drugs, according to figures reported this week.

The trajectory tells a clear story. Ten years ago oncology accounted for a far smaller slice of the hospital pharmacy bill; today it is comfortably the single largest category, and its share keeps rising. The drivers are largely the same ones seen across Europe: a wave of new targeted therapies and immunotherapies that can extend or transform patients' lives, but that arrive with price tags running into tens of thousands of euros per course of treatment.

For the Serviço Nacional de Saúde (SNS, National Health Service), which provides most cancer care in Portugal free or at low cost to patients, the numbers pose a genuine budgeting dilemma. Every euro spent on a breakthrough drug is a euro that must be found within a hospital budget that is also straining to pay for staff, equipment and everything else. Hospital managers have repeatedly warned that medicine costs are among the fastest-growing pressures on their accounts, and oncology sits at the centre of that squeeze.

The rise is not, in itself, bad news. It partly reflects medical progress: diseases that were once quickly fatal are increasingly managed as long-term conditions, and more patients are living long enough to move through several lines of treatment. Portugal has also broadened access to modern therapies through Infarmed (Autoridade Nacional do Medicamento e Produtos de Saúde, the national medicines authority), which negotiates prices and decides which drugs the SNS will fund. Greater spending can mean more people getting effective treatment sooner.

But the sustainability question is real, and it is not unique to Portugal. Across the EU, health systems are wrestling with how to keep paying for expensive innovation without crowding out other care. The tools are familiar — tougher price negotiations with manufacturers, confidential rebate deals, the use of cheaper biosimilar versions once patents expire, and closer scrutiny of which patients benefit most — but none fully resolves the underlying tension between finite budgets and a steady stream of costly new medicines.

For patients and their families, the practical reality is that access to cutting-edge cancer treatment in Portugal is broadly good by international standards, but not instant. New drugs must clear Infarmed's evaluation before hospitals can routinely prescribe them, a process meant to weigh clinical benefit against cost, and there can be delays between a therapy being approved in Europe and being funded here. Advocacy groups regularly press for those timelines to be shortened.

The figures for early 2026 suggest the pressure will only intensify. As more precision therapies reach the market — including gene-based treatments carrying some of the highest prices in medicine — oncology's claim on the hospital drugs budget is set to keep growing. Managing that, without either rationing care or blowing a hole in the health budget, is fast becoming one of the defining challenges for the SNS in the years ahead.